The vav proto-oncogene encodes a protein with multiple modulae domains that enable it to function as a mediator, linking tyrosine signaling to downstream events in hematopoietic cells. Circumstantial evidence suggests that protein-protein interactions exerted by two of these domains, the Src homology 2 (SH2) and the Src homology 3 (SH3), play an important role in the regulation of Vav activity. To study the relevance of the SH3 domain for the function of vav as a transforming gene, we have created several mutations in the SH3 domain located at its carboxy region. Substitution of the non-conserved aspartic acid 797 (to asparagine, D797N) retained the transforming potential of the vav oncogene, whereas substitutions of ®ve highly conserved amino-acids: alanine 789 (to asparagine, A789N), leucine 801 (to arginine, L801R), tryptophan 821 (to arginine, W821R), glycine 830 (to valine, G830V) and valine 837 (to glutamic acid, V837E) greatly reduced its transforming potential. The mutant proteins resemble Vav in many biochemical properties; however, while the transforming mutant protein (D797N) associates with several unidenti®ed proteins in a manner similar to that of Vav, the non-transforming mutant Vav proteins react very poorly with these proteins. Among the known Vav-interacting proteins, hnRNP-K associates with all mutant proteins except A789N and V837E whereas binding of Zyxin to any of the mutant proteins is not aected. Taken together, our results clearly demonstrate that the SH3 domain has a positive eect on vav activity and is needed for vav transformation. The vavSH3C associating protein(s) that are crucial for its activity as a transforming gene have probably not yet been identi®ed.
Introduction
Following binding of a ligand to its receptor, several proteins become phosphorylated on tyrosine residues. This event leads to recruitment of intracytoplasmic messengers which subsequently modulate DNA transcription (Ullrich and Schlessinger, 1990) . Controlled protein-protein interactions that are mediated through speci®c modular domains such as the Src Homology 2 (SH2) and Src Homology 3 (SH3) play key roles in such signaling cascades (Cohen et al., 1995; Pawson and Scott, 1997) . Whereas SH2 domains bind speci®cally to phospho-tyrosine containing proteins, such as stimulated growth factor receptors or other intracellular proteins, the SH3 domains speci®cally associate with proteins that contain short peptide sequences that are rich in proline residues (Cohen et al., 1995; Pawson and Scott, 1997) .
One cytoplasmic signal transducer protein that participates in tyrosine signal transduction events and contains both SH2 and SH3 domains is Vav. Vav is involved in tyrosine signal transduction events in hematopoietic cells (reviewed in where it is normally exclusively expressed (Adams et al., 1992; Bustelo et al., 1993; Coppola et al., 1991; Katzav et al., 1989) . In these cells it participates in the activation of the nuclear factors (NFAT) that are responsible for interleukin-2 (IL-2) expression in T cells (Wu et al., 1995) and it activates Rac-1 dependent stimulation of the JNK/SAPK signaling pathway (Crespo et al., 1996 (Crespo et al., , 1997 . Vav encodes a unique protein that contains a collection of almost all the modular motifs known today to play a role in tyrosine signal transduction, including one SH2 and two SH3 domains (Koch et al., 1991) , a dbl homology domain (DH) that activates GTP-bound proteins of the Rac/Rho-like family of proteins (Adams et al., 1992; Bougski and McCormick, 1993; Galland et al., 1992) and a pleckstrin homology (PH) domain (Musacchio et al., 1993) . It is important for embryogenesis and the normal function of T and B cells Tarakhovsky et al., 1995; Turner et al., 1997; Zhang et al., 1995; and interestingly, it can also function as a transforming gene (Coppola et al., 1991; Katzav et al., 1989 . Indeed, vav was ®rst detected as an oncogene when DNA from esophageal carcinomas was tested for transforming activity (Katzav et al., 1989) .
Accumulating evidence suggests that Vav is involved in protein-protein interactions. Several proteins that interact with Vav via its various encoded domains have recently been identi®ed. The vavSH2 domain associates with the PTK ZAP-70 and SLP-76 from activated T cells (Katzav et al., 1994; Wu et al., 1996) . The aminoterminus SH3 domain (vavSH3N) binds to Grb2, an adaptor molecule that is involved in the ras signaling pathway (Ye and Baltimore, 1994) . The carboxy terminal SH3 domain (vavSH3C) associates with two RNA binding proteins-Heterogeneous Ribonucleoprotein K protein (hnRNP-K; Hobert et al., 1994; Bustelo et al., 1995) and a 45 KDa protein (Bustelo et al., 1995) , Zyxin, a cytoskeleton protein (Hobert et al., 1996a) and Ku-70, a nuclear protein which is the DNA-binding element of the DNA-dependent protein kinase (Romero et al., 1996) . The amino-terminus leucine rich region, which has thus far not been identi®ed as a speci®c modular domain, associates with ENX-1, a putative transcriptional regulator of homeobox gene expression (Hobert et al., 1996b) . These interactions suggest a potential novel mechanism whereby Vav`hooks' cell surface receptor signals to regulatory events involving gene expression.
The only known mode of activation of the vav proto-oncogene as a transforming gene is truncation of its amino-terminus (Coppola et al., 1991; Katzav et al., 1989 . This leaves intact all known functional domains of Vav including the SH2, SH3, DH and PH regions. Our previous studies strongly indicated that an intact SH2 domain is critical for the transforming potential of vav, since mutations in the vavSH2 domain that abrogate its association with tyrosine phosphoproteins also critically impair the transforming activity of the protein (Katzav, 1993) . The contribution of the other modular domains, such as the SH3, for the normal biological activity and transforming ability of vav has not been addressed and is the focus of the studies presented here.
Previously it has been shown that the SH3 region plays a role in transformation, although a somewhat dierent one in various proteins. Thus, mutations in the SH3 domain of the adaptor v-Crk (Mayer and Hanafusa, 1990) reduced its transforming potential whereas deletion/mutations of this domain from the proto-oncogenes Abl (Jackson and Baltimore, 1989; Jackson et al., 1993) and Src (Erpel et al., 1995; Hirai and Varmus, 1990a,b; Kato et al., 1986; Weng et al., 1995) increased their transforming potential. The kinase activity of the SH3 mutant Src proteins increased relative to the intact protein and in addition, the cytoskeleton organization in cells with these proteins changed and resembled the morphology of v-src transformed cells (Erpel et al., 1995; Hirai and Varmus, 1990a,b; Kato et al., 1986; Seidel-Dugan et al., 1992; Weng et al., 1995) . Detailed studies indicated that subtle amino-acid substitutions in the SH3 domain of Src changed their binding properties and therefore resulted in alteration of its biological functions (Erpel et al., 1995; Hirai and Varmus, 1990a,b; Kato et al., 1986; Seidel-Dugan et al., 1992; Weng et al., 1995) .
As alterations in the SH3 domains might aect the biological activity of various proteins dierently, it was dicult to predict how mutations similar to those previously studied may aect the function of vav. For example, a mutation that replaced the amino-acid 832 of vavSH3C from Proline to Leucine (P832L) was shown to eliminate the binding of Vav to hnRNP-K (Hobert et al., 1994) and Zyxin (Hobert et al., 1996) , but did not aect its association with Ku-70 (Romero et al., 1996) . The discriminative binding of various proteins to the same vavSH3C mutant protein could therefore enable us to carefully analyse the contribution of these proteins to the function of Vav. With this in mind, we set out to determine whether several substitutions of conserved amino-acids of vavSH3C alter the transforming potential of Vav and whether the changes in transforming potential depend on the ability of the mutant proteins to interact with other proteins. The data presented in this report indicate that mutant forms of the vav oncogene with speci®c point mutations which alter conserved amino-acids of the SH3 domain greatly impaired the transforming potential of the protein. On the other hand, an amino-acid substituion of a non-conserved residue in the SH3 domain of the vav oncogene retained its transforming potential. These results positively correlated with either retention or loss of the binding properties of the SH3 domain of the mutant proteins. Detailed functional analysis of protein-protein interactions mediated via the various SH3 mutant proteins provide valuable information regarding the processes that underlie signaling and oncogenic events mediated by vav.
Results

Transforming potential of mutant vav SH3C proteins
The vav proto-oncogene is poorly transforming , therefore the vav oncogene was used to detect mutations in the SH3 region that can either retain, decrease or increase the transforming potential of this gene. We chose to introduce the mutations at the vavSH3C region rather than the vavSH3N region, as the SH3C domain is more active in binding proteins than the vavSH3N domain (Katzav et al., unpublished data) .
Sequence alignment of vavSH3C with other SH3 domains revealed that it is almost identical (98%) to the SH3 domain of vav2, another member of the vav family of proteins (Henske et al., 1995) . As there is yet no structural or functional information relating to the SH3 domain of vav2, we searched for additional SH3 domains that resemble that of Vav. Of these, the amino SH3 (SH3N) of Grb2 was found to be highly homologous to vavSH3C (48% identity and 68% homology; Lowenstein et al., 1992;  Figure 1A ).
The overall three dimensional structure of the SH3 domain of various proteins is similar, although dierences in sequence among them exist Hiroaki et al., 1996; Morton et al., 1996; Musacchio et al., 1994; Sicheri et al., 1997; Wittekind et al., 1997; Xu et al., 1997; Yu et al., 1992 Yu et al., , 1994 . In general, the SH3 domain consists of ®ve antiparallel b strands (a to e) that pack to form two perpendicular b sheets. The ligand binding surface is formed by a cluster of conserved hydrophobic residues and is anked by two charged loops which connect strands ba and bb and strands bc and bd, respectively. Although the three dimensional structure of vavSH3C has not been described yet, it is conceivable that it resembles the structure of other SH3 domains. Therefore, based on sequence comparisons, we chose to alter ®ve highly conserved residues that might be critical for the function of Vav and one non-conserved residue of vavSH3 (Figure 1 ). The mutations that were generated in conserved amino-acids are: the alanine at position 789 of proto-vav was changed to asparagine (A789N). This residue is part of the ALYDY sequence which is the most characteristic feature of SH3 domains and was shown to be part of the ®rst b strand (ba) of the SH3 domain of Grb2 (A5; Wittekind et al., 1997;  Figure 1) . The leucine at position 801, which is homologous to a leucine residue that is part of the hydrophobic ligand binding patch of Grb2 (L17; Wittekind et al., 1997) was mutated to arginine (L801R; Figure 1 ). Tryptophan 821 was mutated to arginine (W821R). This is a conserved residue homologous to W36 in Grb2 that was shown to be essential for peptide binding to Grb2 (Wittekind et al., 1997) and is part of the bc strand (Figure 1 ). Glycine at position 830, a conserved residue (G46 in Grb) that is part of the fourth b strand (bd; Wittekind et al., 1997) , was substituted by valine (G830V; Figure  1 ). Valine 837 was mutated to glutamic acid (V837E). This conserved residue (I53 in Grb2; Wittekind et al., 1997) is part of the ®fth b strand (be; Figure 1 ). The non-conserved aspartic acid 797 of proto-vav was substituted by asparagine (D797N; Figure 1 ). Based on sequence alignment (Figure 1 ) and the three dimensional structure of Grb2 (Wittekind et al., 1997) , this residue might correspond to either A13 or D14 in Grb2, neither of which are involved in peptide binding. As detailed in the Materials and methods section, the mutant SH3 regions replaced the intact region of the vav oncogene, thus creating expression vectors that carry the oncogene with a mutant SH3 domain.
Expression vectors containing the mutant vavSH3 plasmids were tested for their transforming potential by the NIH3T3 focus assay (Graham and Van der Eb, 1973) . Of the six mutations introduced, only the D797N mutant protein retained a transforming potential similar to that of the vav oncogene. The rest of the mutant proteins: A789N, L801R, W821R, G830V and V837E yielded only a few (20 ± 116) foci/ mg as opposed to 8.6610 3 foci/mg by the vav oncogene and 2.8610 3 foci/mg by the D797N (Table 1 , Figure 2 ).
To ensure that the dierences in the transforming potential of the various mutant proteins did not stem from a dierence in transfection eciency, we transfected NIH3T3 cells with the various vavSH3C mutant plasmids and the vav oncogene and selected resistant cells in G418 containing media. A comparable number of G418 resistant colonies was obtained with all the transfected expression vectors (data not shown), thus indicating that the dierences in the transforming potential of the mutant proteins is the result of the speci®c mutations that we introduced. Taken together, our results clearly demonstrate that substitution of critical amino-acid residues in the vavSH3C region lead to changes in the transforming potential of the Vav protein. (vavSH3C) with the amino SH3 domain of Grb2 (A) and mutations introduced in vavSH3C (B). (A) The amino-acid residues of the carboxy SH3 domain of Vav (789 ± 845) are compared to the amino acid residues of the amino SH3 domain of Grb2 (Grb2SH3N; residues 5 ± 54; Lowenstein et al., 1992) . The identical residues are highlighted by the letter codes depicted between both SH3 domains and the homologous residues are depicted by +. (B) The amino acids that were mutated and the replacing residues are indicated by an arrow. The resulting plasmids are designated HU1-HU6 respectively. Abbreviations of the amino-acid substituted are: Alanine-A; Asparagine-N; Aspartic acid-D; leucine-L; Tryptophan-W; Arginine-R; Glycine-G; Valine-V and Glutamic Acid-E *NIH3T3 cells were transfected with 100 ng of vav (pSK67) and vavSH3 mutants (HU1 ± HU6), as described in the Materials and methods section. The numbers represent an average of three experiments. Two plates were used in each experiment. u means focus forming units
Expression of vavSH3C mutant proteins in NIH3T3 transfected cells
Since most of the point mutations that we introduced in the vavSH3C region resulted in a low transforming potential, we examined whether the expressed mutant proteins resemble the intact Vav protein in their molecular mass and other characteristics. For that purpose, single foci that appeared in NIH3T3 cells transfected with the SH3 mutant proteins were isolated and propagated in vitro. Cell lysates from individual clones were immunoprecipitated with anti-vav antibodies (Abs). The resulting immunocomplexes were separated on SDS ± PAGE, immunoblotted and hybridized with anti-vav Abs ( Figure 3A ). The mutant vavSH3C proteins: A789N (lanes c ± e), D797N (lanes f ± h), L801R (lane i), W821R (lane j), G830V (lanes k ± m) and V837E (lanes n ± q) were expressed at comparable levels and with a similar molecular mass to that of the vav oncogene (lane b). Our results demonstrated that the mobility of the various mutant proteins resembles that of the intact protein. Thus, no apparent dierences in folding of the protein due to posttranslational modi®cations could be observed.
We have previously observed the constitutive phosphorylation of the Vav protein on tyrosine residues (Katzav, 1993; Margolis et al., 1992) . Therefore, we wished to examine whether the expressed mutant SH3 proteins are also phosphorylated on tyrosine residues under non-induced conditions. Figure 3B ). The various vavSH3C mutant proteins were constitutively phosphorylated on tyrosine residues at a lower level than the intact vav protein ( Figure 3B ), however this is unlikely to be detrimental to their transforming activity.
These experiments demonstrated that the dierent mutant vavSH3C proteins are expressed in the transfected NIH3T3 cells at comparable levels irrespective of their transforming potential. These proteins are of a molecular mass similar to that of the intact protein and are constitutively phosphorylated on tyrosine residues, although to a lesser extent than the wild type vav oncogene.
The mutant vavSH3C proteins are phosphorylated on tyrosine in response to EGF stimulation Although, the SH3 domain does not directly participate in binding to tyrosine phosphoproteins (Katzav et al., 1994) , it is conceivable that the mutations that we introduced in this domain, which is adjacent to the SH2 domain, might in¯uence the activity of Vav as a signal transducer protein. To test this possibility, we analysed whether treatment of cells that carry the mutant SH3 proteins with Epidermal Growth Factor (EGF) leads to an increase in the level of their tyrosine phosphorylation. Quiescent NIH3T3 cells expressing the mutant vavSH3C mutant proteins and the intact vav oncogene were either non-induced (0) or induced with EGF (0.5 mg/ml) for 3 min (3). Lysates of these cells were immunoprecipitated with anti-vav Abs, resolved on a SDS ± PAGE and immunoblotted with anti-Ptyr Abs ( Figure 4A ). As shown in Figure 4A , there is a marked increase in tyrosine phosphorylation of intact Vav, as well as the vavSH3C mutant proteins following stimulation with EGF for 3 min. Thus, à normal' response to induction with EGF that resembles the response of intact Vav, was observed in the cells that carry mutant vavSH3C proteins, although there are some dierences in the degree of phosphor- Figure 2 Transformation by Vav and vavSH3 mutants. NIH3T3 cells were transfected with 100 ng/plate of the following plasmids: (a) none; (b) pSK67 that carries a truncated oncogenic vav cDNA; (c) HU1 that carries the A789N mutant; (d) HU2 that carries the D797N mutant; (e) HU3 that encodes the L801R mutant; (f) HU4 that carries the W821R mutant; (g) HU5 that carries the G830V mutant; and (h) HU6 that carries the V837E mutant. Fourteen days following the transfection, the cells were stained with Giemsa as described in the Materials and methods section and their morphology is shown ylation followed extended exposure to the growth factor.
To test whether the mutant vavSH3C proteins associate with tyrosine phosphorylated proteins in a manner similar to that of the intact vav protein, NIH3T3 cells expressing Vav and vavSH3C mutant proteins were lysed and immunoprecipitated with antivav Abs. The immunoprecipitates were then incubated with lysates of NIH3T3 cells overexpressing EGFR (HER14), induced (+) with EGF for 2 min or noninduced (7). The bound complexes were washed three times, resolved on SDS ± PAGE and immunoblotted with anti-Ptyr Abs ( Figure 4B ). Intact Vav, as well as the mutant vavSH3C proteins, associated with a 170 kd tyrosine phosphorylated protein only when the HER14 cells were induced with EGF ( Figure 4B ). This protein was con®rmed to be EGF receptor (EGFR) by immunoblotting with anti-EGFR Abs ( Figure 4C ).
Taken together, our experiments clearly show that the vavSH3C mutant proteins, irrespective of their transforming potential, resemble the intact protein with regards to their response to growth factor stimulation and association with tyrosine phosphorylated proteins.
Association of intact and mutant vavSH3C with other proteins
Mutations/deletions in the SH3 domain of various proteins have been shown to aect their ability to associate with other proteins (Bustelo et al., 1995; Clark et al., 1992; Erpel et al., 1995; Hirai and Varmus, 1990a,b; Hobert et al., 1994; 1996a,b; Jackson and Baltimore, 1989; Jackson et al., 1993; Kato et al., 1986; Mayer and Hanafusa, 1990; Romero et al., 1996 The immunoprecipitates were then incubated with lysates of cells overexpressing EGFR (HER14) that were either non induced (7) or induced (+) with 0.5 mg/ml EGF for 2 min. The proteins were then resolved on SDS ± PAGE and immunoblotted with anti-Ptyr Abs. (C). The immunoblot of lanes a and b was stripped and rehybridized with anti EGFR Abs (C). The arrow indicates the location of the EGFR expressed the vavSH3C intact and mutant domains as glutathione-S-transferase (GST) bacterial fusion proteins in pGEX-2TK (Kaelin et al., 1992) . The various vavSH3C domains (nucleotides 2324 ± 2501) were ampli®ed by PCR and subcloned between the EcoRI and BamHI restriction sites of pGEX-2TK. GST, intact vavSH3C and the mutant vavSH3C proteins were expressed as bacterial fusion proteins, immobilized to glutathione sepharose beads and then bound to lysates of 35 S-Methionine metabolically labeled Jurkat T cells ( Figure 5A ). The results clearly indicate that the overall binding to vavSH3C and D797N proteins is similar, though not identical. Four proteins of 46, 60, 97 and 120 kd molecular mass that bind to vavSH3C also associate with D797N. We can observe that there are additional proteins that associate with the bacterial fusion D797N protein, but do not associate with wild type vavSH3C ( Figure 5A ). The mutant bacterial fusion proteins A789N, G830V and V837E react very poorly with the proteins bound by wild type (Figure  5a ). L801R and W821R bind numerous proteins, however they lose the binding to major proteins such as the 46, 60, 97 and 120 kd that bind to intact vavSH3C and D797N. The binding pattern of lysates of NIH3T3 cells to vavSH3C and vavSH3C mutant proteins was similar to that of Jurkat lysates (data not shown). Thus, the mutations that we have introduced in the vavSH3C alter its binding properties. In addition, there are marked dierences in the protein binding properties among the various mutant proteins. The D797N mutant protein that is highly transforming also retains its protein binding properties, whereas the vavSH3C mutant proteins that are defective in their transforming potential are also defective in their protein binding properties.
As the method that we used for detection of binding proteins to vavSH3C and vavSH3 mutant proteins provides only crude information, we wished to examine whether the mutant proteins retained or lost their binding properties to speci®c proteins known to bind to vavSH3C. For that purpose, equivalent amounts of the GST bacterial fusion proteins that carry the vavSH3C proteins were immobilized on glutathione sepharose beads and incubated with lysates of nonlabeled Jurkat T cells. The bound proteins were separated on SDS ± PAGE and immunoblotted with Abs against either hnRNP-K ( Figure 5B ) or anti-Zyxin ( Figure 5C ), two proteins known to bind to vavSH3C. The use of speci®c Abs enhanced the sensitivity of our assay. The intact vavSH3C protein and the mutant SH3 domains of D797N, L801R, W821R and G830V were found to associate with hnRNP-K, while the SH3 domains of A789N and V837E have lost their ability to bind this protein ( Figure 5B ). In addition, the D797N mutant region binds hnRNP-K to the same extent as the intact vavSH3C. When exposed to a similar amount of cell lysate, the mutant proteins bind this protein much less well. D797N, that binds hnRNP-K to the same extent as the intact vavSH3C, retains its transforming potential whereas the other vavSH3C mutant proteins that either bind this protein to a lower extent or lose their binding capacity completely have only minimal transforming potential. The question of whether binding to hnRNP-K is associated with vav transformation will be further discussed.
The vavSH3C and the various vavSH3 mutant proteins were also tested for their association with Zyxin, a cytoskeletal protein ( Figure 5C ). The experiment was conducted in a similar fashion to that described above ( Figure 5B ), except that Zyxin Abs were used for immunoblotting. Since all the mutants proteins bound Zyxin albeit at various levels, association with Zyxin appears not to be hampered by the mutations that we introduced and is probably not related to the transforming potential of vav.
Discussion
Vav, a signal transducer protein, contains multiple modular domains that can function in various signaling cascades . To study the relevance of one of these domains, the SH3 region (vavSH3C), for the Figure 5 Association of intact and mutant vavSH3C proteins with various proteins. Lysates of 35 S-Methionine labeled Jurkat T cells were incubated with bacterial fusion proteins expressing GST; vavSH3C and vavSH3C mutant proteins immobilized on glutathione-Sepharose beads. The bound proteins were then resovled on SDS ± PAGE, the gel was dried and exposed to autoradiography (A). Molecular weight (MW610 3 ) markers are: phosphorylase b (97), bovine serum albumin (69) and ovalbumin (46). Lysates of non-labeled Jurkat T cells were incubated as described above (A). The bound proteins were then resolved on SDS ± PAGE and the gel was immunoblotted with anti hnRNP-K Abs (B) or anti-Zyxin Abs (C). The immunoblots were developed by ECL. Arrows indicate the location of the hnRNP-K, a protein of 65 kd molecular weight (B) and Zyxin, a protein of 85 kd molecular weight (C) function of vav as a transforming gene, we have substituted ®ve highly conserved amino acids and one non-conserved residue in this region. The resulting mutant proteins were tested for their transforming activity. Our results show that substitution of critical amino-acid residues at the vavSH3C region lead to changes in the transforming potential of the mutant proteins, whereas alteration of a non-conserved aminoacid does not aect the properties of the wild type protein. Among the six mutants that we created, D797N was the only one that retained a transforming potential similar to that of the vav oncogene, whereas the rest of the mutant proteins (A789N, L801R, W821R, G830V and V837E) exhibited a low transforming potential (Table 1, Figure 2 ). The number of G418 resistant NIH3T3 cells transfected with wild type and the mutant proteins was similar (data not shown), thus suggesting that the dierences in the transforming potential of the mutant proteins does not re¯ect dierences in their transfection eciencies. Hence, the SH3 domain has a positive eect on vav activity and is needed for vav transformation.
Perturbations in the SH3 domain of other proteins were also shown to aect their transforming potential (Erpel et al., 1995; Hirai and Varmus, 1990a,b; Jackson and Baltimore, 1989; Jackson et al., 1993; Kato et al., 1986; Mayer and Hanafusa, 1990; Seidel-Dugan et al., 1992; Weng et al., 1995) . In these cases the mutations/ deletions were shown to aect the biochemical properties such as enzymatic activity of the mutant proteins (Erpel et al., 1995; Hirai and Varmus, 1990a,b; Mayer and Hanafusa, 1990; Seidel-Dugan et al., 1992) . We therefore wished to examine whether the biochemical properties of the mutant SH3 proteins dier from those of wild type Vav. We ®rst tested whether the mutant proteins can be induced in response to activation with EGF ( Figure 4A ) and bind the activated tyrosine phosphorylated EGFR like the wild type protein ( Figure 4B and C) . By both these criteria the mutant proteins were found to be similar to wild type Vav. The mutant proteins were also found to be constitutively phosphorylated on tyrosine residues, although at a somewhat lower level than the wild type Vav ( Figure  3B ). Thus, unlike the SH3 domain of Src (Fumagali et al., 1994; Richard et al., 1995; Weng et al., 1995) , mutations in the vavSH3C do not aect the activity of Vav as a signal transducer protein, as judged by the experiments presented here.
The SH3 domain is known to participate in proteinprotein interactions (Cohen et al., 1995; Pawson and Scott, 1997) . Therefore, it was conceivable that the mutations that we introduced in the vavSH3C region led to changes in its binding to certain protein(s), as we have previously shown to be the case with another modular domain of Vav, the SH2 region (Katzav, 1993) . Indeed, our results clearly indicate that the mutations introduced in conserved amino-acids greatly changed the binding properties of the mutant proteins. Thus, mutant proteins A789N, G830V and V837E hardly associated with any proteins, whereas L801R and W821R bind numerous proteins, though they lose the ability to bind major proteins that associated with wild type vavSH3C and D797N ( Figure 5A ). The substitution in the non-conserved amino-acid residue D797 resulted in a transforming mutant protein (D797N) that binds several unidenti®ed proteins (46, 60, 97 and 120 kd) in a fashion similar to the binding of wild type vav with these proteins ( Figure 5A) . Hence, the mutant protein (D797N) that is highly transforming also retains its protein binding properties, whereas the vavSH3C mutant proteins that are defective in their transforming potential are also defective in their protein binding properties.
Our results are in good agreement with other studies that showed that mutation/deletions in the SH3 domain of various proteins aect their ability to associate with other proteins (Hirai and Varmus, 1990a,b; Jackson and Baltimore, 1989; Jackson et al., 1993; Kato et al., 1986; Mayer and Hanafusa, 1990; Seidel-Dugan et al., 1992; Weng et al., 1995; Xie et al., 1995) . For instance, deletion of the SH3N in Grb2 that is highly homologous to vavSH3C (Figure 1A ), resulted in a mutant protein that no longer associates with Sos and HER-2/Neu but retains its association with Shc (Xie et al., 1995) . Another example is substitution in Src of D99, a negatively charged residue of the SH3 domain, to asparagine (N), which reduced the binding of most proteins that usually associate with its SH3 domain (Weng et al., 1995) . At the same time there was only a more moderate decrease in binding to a limited number of proteins, including hnRNP-K and the tyrosine phospho-protein, p68 (Weng et al., 1995) . A dierent substition of D99, to lysine, a positively charged residue (D99K), resulted in an almost complete loss of binding to p68 and did not allow Src to take its inactive conformation, thus leading to deregulation of Src activity (Erpel et al., 1995) . The negative charge in the D99 position is probably involved in binding to positively charged residues that contain peptides with an arginine (Arg) at position 73 (Weng et al., 1995) . Obviously, it is highly signi®cant which residue substitutes the D99 as one allows some binding to proteins (D99N) while others allow no binding at all (D99K).
Although, we have not substituted the residue in vavSH3C that corresponds to D99, it is clear from our results that the mutations that we introduced in other conserved amino-acid residues of vavSH3C altered the binding properties of the mutant proteins. Based on sequence alignment ( Figure 1A) , and the three dimensional structure of the SH3N of Grb2, that is highly homologous to vavSH3C complexed with its cognate peptide (Wittekind et al., 1997) , only the mutated amino-acid residue W821 in vavSH3C might be directly involved in binding to proteins. The rest of the mutated conserved amino-acid residues are probably not directly involved in protein binding, yet they might be critical for the proper folding of the protein. Similar results were obtained with mutant proteins of vavSH2 that carried substitutions of aminoacid residues that are not thought to be directly involved in association with tyrosine phospho-proteins, yet those were also defective in their binding properties (Katzav, 1993) . The reason for the differences in the pattern of binding between the various mutants might either be the result of the amino-acids that were introduced instead of the existing ones, as was shown for D99 of Src, or might depend on the location of the mutated residues in the SH3 region. Thus, it is noteworthy that the substitutions to residues which are either uncharged or hydrophobic such as asparagine (A789N) an uncharged molecule, valine (G830V), an amino-acid residue with a hydrophobic side chain, and glutamic acid (V837E) an amino-acid residue with a highly acidic side chain, resulted in mutant proteins that hardly associate with other proteins, whereas mutations to arginine, a residue that has a long basic side chain, yielded mutant proteins (L801R and W821R) that bind numerous proteins that dier from the ones that bind to wild type vavSH3C and D797N ( Figure 5A ). Our ability to speculate in depth on these results depend largely on resolving the yet unknown three dimensional structure of vavSH3C, especially when it is complexed with its cognate peptide. Once this information will become available, we will be able to determine the role of the various amino-acid residues in the vavSH3C region with more certainty.
The mutant SH3 domain of D797N, as well as those of L801R, W821R and G830V were found to associate with hnRNP-K, while the SH3 domains of A789N and V837E have lost their ability to bind this protein ( Figure 5B ). In addition, there are dierences in the extent of binding to this protein. Whereas, the D797N mutant region binds hnRNP-K to the same extent as intact vavSH3C, the mutant proteins (L801R, W821R and G830V) bind this protein less well. From our experiments, it seems that there is no clear correlation between association with hnRNP-K and vav transformation. The possibility that there might be a minimal amount of hnRNP-K that is needed to be bound to the SH3 domain in order for the protein to be eective in transformation was ruled out. Thus, Bustelo et al. (1995) showed that overexpression of hnRNP-K in NIH3T3 ®broblasts did not lead to an increase in the transforming activity of vav and, in addition, a dominant negative mutant of hnRNP-K did not block transformation by vav. Therefore, based on our results and on Bustelo's report (Bustelo et al., 1995) , we can conclude that hnRNP-K is not directly involved in transformation by vav.
Another protein that associates with the vavSH3C domain is Zyxin, a cytoskeleton protein (Hobert et al., 1996b) . Our experiments showed that all the mutant proteins bound Zyxin, albeit at various levels ( Figure  5C ), thus implying that the association with Zyxin is not hampered by the mutation that we have introduced and is probably not related to the transforming potential of vav.
Ku-70, a nuclear protein which is the DNA-binding element of the DNA-dependent protein kinase was found to associate with the SH3C of Vav (Romero et al., 1996) . Although, we did not test its binding to the mutant proteins, it is unlikely that its association with Vav is relevant for transformation. This is based on the fact that Ku-70 associates with a mutant form of vavSH3C, P832L that was found to be non-transforming (Katzav et al., unpublished data) . Thus, the binding of Ku-70 to Vav is probably not important for the transformation by Vav.
Based on our results, we believe that the protein(s) that bind to vavSH3C and are crucial for its activity as a transforming gene, have not yet been identi®ed. These protein(s) may be among those that we observe to associate with the wild type vavSH3C and the transforming mutant (D797N), but not the non-transforming mutants ( Figure 5A ). The mutations that we introduced in the vavSH3C region will undoubtedly serve as a powerful tool in the search for such proteins. The isolation of the proteins that associate with vavSH3C and their analysis will clarify whether the introduced mutations in vav aect its activity by impairing a functional residue that is directly involved in protein-protein interactions, or by causing a conformational change in the protein. More importantly, only when the proteins that associate with vavSH3C will be isolated, and their contribution to the activity of vav will be assessed, will we be able to fully understand the mechanisms of transformation by the signal transducer protein, vav.
Materials and methods
Site directed mutagenesis
We used the Chamelon double-stranded, site directed mutagenesis kit (Stratagene) to create point mutations in the carboxy SH3 domain of vav (vavSH3C) in the full length protovav subcloned in Bluescript KS 7 plasmid (pSK114). The selection primer: 5'-GAGCCACTAGTTCTGGAGCGGC-CGCC-3' was used to change an XhoI restriction site whereas the following primers were used to change speci®c amino-acids in the vavSH3 domain. The oligonucleotides used to create the mutations are: A789N-5'-TTTGGCACAGCCAAAAACC-GCTATGACTTC-3'; D797N-5'-TTCTGCGCCCGTAAC-CGTTCAGAGCT-3'; L801R-5'-GACCGTTCAGAGCGG-TCGCTGCAAGGAG-3'; W821R-5'-CAGCAAGGCTG-GAGGCGAGGGGAG-3'; G830V-5'-ATGGCCGGGTTG-TCTGGTCCCTGC-3'; V837E-5'-CCTGCCAACTACG-AGGAGGAAGATTATTC-3'. The amino-acids that were substituted by the dierent primers are underlined. The mutagenesis was created according to the manufacturer's instructions. Mutants were veri®ed by dideoxy chain termination sequencing method (Sanger et al., 1977) .
Mammalian expression plasmids
The vav expression plasmids used in this report are as follows: (1) pSK67 contains the truncated oncogenic vav cDNA subcloned in the correct orientation at the EcoRI site of the mammalian expression vector, pMexneo (Katzav et al., 1989) ; (2) pSK68 contains the truncated oncogenic vav cDNA subcloned into pMexneo in the opposite orientation to pSK67 (Katzav et al., 1989) ; (3) The expression vectors that contain a mutant SH3 domain in the transforming vav gene (HU1-HU6) were created as follows: a 1.2 kbp KpnI fragment that contains the mutant vavSH3C created in pSK114 replaced the intact 1.2 kbp KpnI fragment of the transforming vav in pSK68. Then, an EcoRI fragment that contains the truncated transforming vav with a mutant SH3C was subcloned at the correct orientation in the EcoRI site of pMexneo. The various expression vectors were designated according to the mutation in the vav oncogene as indicated in Figure 1 .
Cell culture
The cell lines used in this study are: NIH3T3 murine ®broblast, NIH3T3 cells that express the vav oncogene (K49; Katzav et al., 1989) , NIH3T3 cells that express the vavSH3C mutant proteins and NIH3T3 cells that overexpress the human EGFR (HER14; Honegger et al., 1987) . These cell lines were grown in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% calf serum. Jurkat T cells were grown in RPMI medium containing 10% fetal calf serum (FCS).
Gene transfer assay
Two610 5 NIH3T3 murine ®broblasts were seeded in dishes 24 h prior to gene transfer in DMEM containing 10% calf serum. Cells were transfected with various doses of either truncated vav(pSK67) or vavSH3 mutants (HU1-HU6) and 20 mg of calf genomic DNA as carrier by the calcium phosphate method (Graham and Van der Eb, 1973) . Twenty-four hours following gene transfer, cells were washed twice and grown for an additional 14 days in DMEM containing 5% calf serum. To determine transfection eciency, cells were split 48 h after transfection in DMEM containing 10% calf serum and 500 mg/ml of G418. Transformed foci and G418 resistant colonies were scored and dishes were stained in Giemsa. To stain cells, plates were washed twice with 10 ml of phosphate buered saline, ®xed in 10 ml methanol for 10 min and then stained with a 2% solution of Giemsa for 20 min.
Cell labeling
NIH3T3 cells were labeled with 35 S-Methionine (50 mci/ml; Amersham) for 3 h in methionine-free medium containing 10% dialyzed calf serum (GIBCO), washed with phosphate-buered saline and lysed as described.
Immunoprecipitation and immunoblotting
Cells were lysed in 1% Triton X-100 lysis buer with protease and phosphatase inhibitors. Cell extracts were immunoprecipitated for 1 ± 5 h with antibodies as indicated. The resulting immune complexes, harvested with protein-A sepharose beads (Pharmacia), were resolved by SDS ± PAGE on an 8% acrylamide slab gel. Proteins were then transferred to nitrocellulose and immunoblotting was performed with Abs described. Blots were detected with either [
125 I] protein A or by ECL as indicated and followed by autoradiography as described before (Katzav, 1993) .
Construction of pGEX-2TK SH3 expression plasmids
The vavSH3 bacterial fusion protein DNA cosntructs were created by polymerase chain reaction (PCR) and standard recombinant technology using the following primers: 5'-CCGGGGGAATTCGATGGAGGTGTTTCAG-3'; 5'-GG-CCCCGGATCCCAAGGCACCAGGGCTAC-3'. The PCR products were sequenced and cloned between the BamHI and EcoRI restriction sites of the Glutathione-S-transferase (GST) fusion protein vector pGEX-2TK (Kaelin et al., 1992) . Mutant vavSH3C constructs were created in a similar fashion.
Immobilization of bacterial fusion proteins on glutathione sepharose beads
Fusion proteins were puri®ed from transformed E. coli bacteria that were stimulated with isopropyl-b-D-thio galactopyranoside (IPTG) at a concentration of 0.3 mM. After 2 h additional growth, bacteria were lysed by sonication in a solution containing ± 10 mM Tris HCl (pH 8.0); 0.5% Nonidet P-40, 100 mM sodium chloride, 20 mM EDTA (pH 8.0) and protease inhibitors. Lysed bacteria were spun for 15 min 15K at 48C and the supernatant was immobilized on glutathione sepharose beads (Pharmacia). Bound proteins were washed three times with the lysis buer and then used in the dierent binding assays (Katzav et al., 1994; Margolis et al., 1992) .
Binding of cell lysates to GST, vavSH3 and vavSH3 mutant fusion proteins immobilized on glutathione sepharose beads Cell lysates were incubated with the appropriate fusion proteins immobilized on glutathione sepharose beads (5 mg) as described previously (Katzav et al., 1994; Margolis et al., 1992 ). The bound proteins were then resolved on SDS ± PAGE. When lysates of 35 S-Methionine labeled cells were used, the gels were dried and exposed to autoradiography. When lysates of non-labeled cells were used the gels were blotted onto nitrocellulose which was hybridized with the indicated Abs proteins were detected with [
125 I]protein A or by ECL as indicated and followed by autoradiography as described before (Katzav, 1993 (Katzav, , 1994 Margolis et al., 1992) .
In vitro binding assays
Lysates from 5610 6 subcon¯uent NIH3T3 cells carrying the vav oncogene and the vavSH3C mutants plasmids were immunoprecipitated with anti-vav Abs and washed three times with HNTG (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, Glycerol 10%). The immunoprecipitates were then incubated with lysates from 1610 7 HER14 cells, either induced with EGFR or non-induced, for 90 min at 48C. Bound proteins were washed three times, separated by 8% SDS ± PAGE, transferred to nitrocellulose and immunoblotted (Katzav, 1993) .
EGF stimulation
NIH3T3 cells transfected with either vav or the vavSH3C mutants were grown to subcon¯uence, then starved in DMEM containing 5 mg/ml insulin and transferrin for 48 h. Cells were then treated with DMEM containing 0.5 mg/ml mouse EGF for 3 min at 378C. Cells were washed twice with PBS and lysed as indicated. For induction of EGFR in HER14 cells, cells were treated as described above except that they were stimulated with 100 ng/ml human EGF for 2 min on ice (Honegger et al., 1987) .
Activation of Jurkat T cells, immunoprecipitation and immunoblotting
Jurkat T cells at 2610 8 cells/ml were activated with the anti CD3e mAb OKT3 (1 : 100; American Type Tissue Culture Collection) for 1 min at 378C.
Antibodies
Anti-vav antibodies were raised in rabbits against a speci®c peptide of vav, residues 528 ± 541 . Other antibodies used are: Anti-phosphotyrosine (Ptyr), 4G10 (UBI); anti EGFR Abs (Sigma); anti-Zyxin, a kind gift from Dr MC Beckerle, University of Utah (USA); anti hnRNPK, a kind gift from Dr JE Celis, University of Aarhus (Denmark).
